A kind of amino lipid compound, preparation method and application thereof

By developing a diverse library of amine-based lipid compounds and preparation methods, the toxicity and adaptability of gene vectors in gene therapy are solved, and efficient and safe gene delivery is achieved, suitable for different nucleic acid substances and cellular structures.

CN113999184BActive Publication Date: 2024-11-12SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202010128563.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-02-28
Publication Date
2024-11-12
Estimated Expiration
2040-02-28

AI Technical Summary

Technical Problem

Existing gene vectors have toxicity, immunogenicity and safety problems in gene therapy, and it is difficult to adapt to the needs of nucleic acid substances and cell structures of different structures, making it difficult to take into account both the transfection efficiency and safety.

Method used

Develop a library of amine-based lipid compounds to prepare diverse and efficient amine-based lipid compounds through diversified functional groups and flexible preparation methods to prepare lipid particles to form suitable for delivery of different nucleic acid substances. Platform delivery system.

Benefits of technology

It achieves efficient and safe gene delivery, and the diversity and flexible preparation methods of amine-based lipid compounds are suitable for different nucleic acid substances and cell structures, improving the pertinence and effectiveness of the delivery system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113999184B_ABST
    Figure CN113999184B_ABST
Patent Text Reader

Abstract

The present disclosure relates to an amine lipid compound, a preparation method thereof and a lipid particle comprising the amine lipid compound, wherein the amine lipid compound has the characteristics of strong functional group diversity and large number, and the preparation method of the amine lipid compound has the advantages of easy availability of raw materials, mild reaction conditions, good reaction selectivity, high reaction yield, low instrument and equipment requirements and simple operation. The present invention also relates to a lipid particle containing the amino lipid and its use for delivering a bioactive agent to a cell. The present invention also relates to the use of a lipid particle containing a cationic amino lipid as a drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to an amine lipid compound, a preparation method thereof and a lipid particle comprising the amine lipid compound. The lipid particle can be used to deliver a bioactive agent into a cell. The present invention also relates to the use of the lipid particle containing the amine lipid as a drug. Background Art

[0002] Gene therapy refers to the process of introducing target genetic material into specific tissue cells through appropriate vectors for appropriate expression, replacing or correcting the disorder in the structure or function of one's own genes, killing diseased cells or enhancing the body's ability to eliminate diseased cells, etc., so as to achieve the purpose of treatment. However, nucleic acid substances are easily hydrolyzed by nucleases and carry a large amount of negative charge, which is not conducive to cell phagocytosis. Therefore, it is particularly important to research and develop efficient, safe and tissue-specific gene delivery systems.

[0003] The gene vectors currently under study can be divided into viral vectors and non-viral vectors. Although viral vectors have high transfection efficiency, their toxicity, immunogenicity and serious safety issues limit their application in clinical treatment. Non-viral vectors have attracted the attention of more and more experts and scholars due to their advantages such as easy preparation, transportation, storage, safety, effectiveness and non-immunogenicity.

[0004] Non-viral vectors are mainly divided into cationic polymers and cationic liposomes. Cationic polymers refer to synthetic or naturally formed polymers containing cations. Polyethyleneimine (PEI) is one of the most common cationic polymer non-viral gene vectors. It can wrap negatively charged genes and form nanocomplexes, which can enter cells through endocytosis and escape through lysosomes to show good transfection efficiency. However, PEI has high cytotoxicity, and the toxicity is proportional to the transfection efficiency. Although chitosan has good biosafety, its transfection efficiency is low. Cationic lipid particles are artificially prepared phospholipid vesicles with double-layer membranes. The main difference between these lipid particles is the difference in their charge and microstructure. When the target DNA is mixed with this lipid particle, the DNA will condense and form a relatively stable lipid particle DNA complex (lipoplex) with it. Because lipid particles have properties similar to biological membranes, when the lipid particle DNA complex contacts the cell membrane, it enters the cell through endocytosis. In addition to high transfection efficiency, lipid particles have no immunogenicity, low cytotoxicity, and are easy to prepare. Therefore, cationic lipid particles have become one of the most commonly used vectors for gene transfection today.

[0005] Although there have been many reports on cationic lipid particles and commercial transfection reagents are available, the subtle differences in the structure of the gene to be delivered require the charge and subtle structure of the lipid particles to match them. It is difficult for one or several transfection reagents to be suitable for the delivery of all genetic materials. The subtle differences in the cell structure of the genetic material to be transferred also require lipid particles of different properties to match them. Therefore, relative to the rapid development of gene therapy and the huge market demand, there is an urgent need to develop a small platform delivery system to meet the delivery needs of nucleic acid materials with different structures. Summary of the invention

[0006] Technical issues

[0007] One object of the present invention is to provide an amino lipid compound library, which has the characteristics of strong functional group diversity and large number.

[0008] Another object of the present invention is to provide a method for preparing a novel amino lipid compound, which has readily available raw materials, mild reaction conditions, good reaction selectivity, high yield, low instrument and equipment requirements, and simple operation.

[0009] Another object of the present invention is to provide a lipid particle comprising the amino lipid compound.

[0010] Technical Solution

[0011] One aspect of the present invention provides an amine lipid compound, which is a compound represented by the following chemical formula I:

[0012] [Chemical Formula I]

[0013]

[0014] In Formula I, R 1 and R 2 are the same as or different from each other and are each independently selected from C6-C 24 Alkyl, C6-C 24 Alkenyl, C6-C 24 Alkynyl and C4-C 24 Acyl, wherein the C6-C 24 Alkyl, the C6-C 24 Alkenyl, the C6-C 24 Alkynyl and the C4-C 24 The acyl group is optionally substituted with a C1-C6 hydrocarbon group;

[0015] X 1 , X 2 and X 3 are the same as or different from each other and are each independently selected from C, N, O, S, S=O, S(=O)2 and SS;

[0016] When X 1 When it is C, m=2, and two R 6 The same or different from each other; when X 1 When it is N, m=1; when X 1 When it is O, S, S=O, S(=O)2 or SS, m=0;

[0017] When X 2 When it is C, n=2, and two R 7 The same or different from each other; when X 2 When it is N, n=1; when X 2 When it is O, S, S=O, S(=O)2 or SS, n=0;

[0018] When X 3 When C, p = 2, and two R 8 The same or different from each other; when X 3 When it is N, p = 1; when X 3 When it is O, S, S=O, S(=O)2 or SS, p=0;

[0019] R 3 and R 4 are the same as or different from each other and are each independently selected from C1-C 12 Alkyl, C2-C 12 Alkenyl and C2-C 12 Alkynyl, wherein the C1-C 12 Alkyl, the C2-C 12 Alkenyl and the C2-C 12 The alkynyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 combine with each other to form an optionally substituted 4- to 10-membered heterocyclic ring comprising 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen;

[0020] R 5 Does not exist, or R 5 is hydrogen or C1-C 12 Alkyl to provide a quaternary amine;

[0021] R 6 , R 7 , R 8 is hydrogen or C1-C 12 alkyl;

[0022] L is C1-C 12 Alkylene, C2-C 12 Alkenylene or C 2- C 12 Alkyne, wherein the C1-C 12Alkylene, the C2-C 12 Alkenylene and the C2-C 12 The alkynylene group is optionally substituted with one or more substituents selected from hydrocarbyl, carboxyl, acyl and alkoxy, or L is an optionally substituted 4- to 10-membered heterocyclic ring containing a heteroatom selected from nitrogen, sulfur and oxygen.

[0023] More specifically, the present invention provides an amino lipid compound, wherein, in Chemical Formula I, X 1 C, R 6 is H, m = 2; or X 1 N, R 6 is H, m = 1; or X 1 is O, S, S=O, S(=O)2 or SS, m=0; X 2 C, R 7 is H, n = 2; or X 2 N, R 7 is H, n = 1; or X 2 For O, S, S=O, S(=O)2 or SS, n=0; 3 C, R 8 is H, p = 2; or X 3 N, R 8 is H, p = 1; or X 3 It is O, S, S=O, S(=O)2 or SS, p=0.

[0024] More specifically, the present invention provides an amino lipid compound, wherein, in Chemical Formula I, R 1 and R 2 are the same or different from each other and are each independently C6-C 24 Alkyl; X 1 N, R 6 is H, m = 1; or X 1 is S, m=0; X 2 N, R 7 is H, n = 1; or X 2 S, n = 0; X 3 N, R 8 H, p = 1; R 3 and R 4 are the same or different from each other and are each independently C 1- C 12 Alkyl, wherein the C 1- C 12 The alkyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 are combined with each other to form an optionally substituted 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen; R5 Does not exist.

[0025] Another aspect of the present invention provides a method for preparing an amino lipid compound, the method comprising the following steps: (1) reacting cyanuric chloride with R at a temperature of -30°C to 30°C in the presence of a base as an acid-binding agent; 1 -X 1 The compound represented by H is subjected to a first reaction to obtain a first intermediate, wherein X 1 is NH or S; (2) without isolating the first intermediate, adding R 2 -X 2 The compound represented by H is subjected to a second reaction in the presence of a base as an acid-binding agent to obtain a second intermediate, wherein X 2 is NH or S; (3) without isolating the second intermediate, adding H2N-(CH2)q-NR 3 R 4 The diamine represented by is subjected to a third reaction under heating conditions to obtain an amino lipid compound; wherein q is an integer from 1 to 12.

[0026] Another aspect of the present invention provides a lipid particle comprising the above-mentioned amino lipid compound.

[0027] Beneficial Effects

[0028] The amino lipid compounds of the present invention have the characteristics of strong functional group diversity and large number. The preparation method of the amino lipid compounds has the advantages of easy availability of raw materials, mild reaction conditions, good reaction selectivity, high reaction yield, low instrument and equipment requirements and simple operation. The preparation method of the present invention is very general and can be used for the rapid synthesis of cationic amino lipid compound libraries and can be used for rapid cell-based screening experiments in a very inexpensive manner.

[0029] The amino lipid compound functional group types and combinations provided by the present invention are diverse. Through conventional screening for characteristics such as transfection efficiency, cytotoxicity, adhesion of the agent to be delivered to the cell, stability of the lipid particles, and size of the lipid particles, it can be conveniently applied to the delivery of different nucleic acid substances to different cells, thereby improving the specificity and effectiveness of the delivery system.

[0030] The amino lipid compound of the present invention can be synthesized with high throughput and high efficiency by using a combinatorial chemistry method, and the synthesis method is simple and has a high yield.

[0031] The present invention provides lipid particles containing the amino lipid and use thereof for delivering bioactive agents into cells. The present invention also includes use of lipid particles containing cationic amino lipids as drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Microscopic images of HEK293 cells treated with a reference reagent (Lipofectamine 2000) and S8N12D6 according to Example 2 are shown, wherein: Figure 1 (a) shows the bright field image of HEK293 cells treated with a reference reagent (Lipofectamine 2000). Figure 1 (b) shows a bright field image of HEK293 cells treated with S8N12D6 according to Example 2; Figure 1 (c) shows the Hoechst staining image of HEK293 cell nuclei treated with a reference reagent (Lipofectamine2000); Figure 1 (d) shows the Hoechst staining image of HEK293 cell nuclei treated with S8N12D6 according to Example 2, Figure 1 (e) shows the GFP image of HEK293 cells treated with a reference reagent (Lipofectamine 2000). Figure 1 (f) shows the GFP image of HEK293 cells treated with S8N12D6 according to Example 2. DETAILED DESCRIPTION

[0033] Hereinafter, the present specification will be described in more detail.

[0034] The term "optionally substituted" as used herein means that one or more hydrogen atoms attached to an atom or group are independently unsubstituted or substituted by one or more, for example one, two, three or four substituents, the substituents being independently selected from: deuterium (D), halogen, -OH, mercapto, cyano, -CD3, C1-C6 alkyl (preferably C1-C3 alkyl), C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl (preferably C3-C8 cycloalkyl), aryl, heterocyclyl (preferably 3-8 membered heterocyclyl), heteroaryl, aryl C1-C6 alkyl-, heteroaryl C1-C6 alkyl, C1-C6 haloalkyl, -OC1-C6 Alkyl (preferably -OC1-C3 alkyl), -OC2-C6 alkenyl, OC1-C6 alkylphenyl, C1-C6 alkyl-OH (preferably C1-C4 alkyl-OH), C1-C6 alkyl-SH, C1-C6 alkyl-O-C1-C6 alkyl, OC1-C6 haloalkyl, NH2, C1-C6 alkyl-NH2 (preferably C1-C3 alkyl-NH2), -N(C1-C6 alkyl)2 (preferably -N(C1-C3 alkyl)2), -NH(C1-C6 alkyl) (preferably -NH(C1-C3 alkyl)), -N(C1-C6 alkyl) (C1-C6 alkylphenyl ), -NH(C1-C6 alkylphenyl), nitro, -C(O)-OH, -C(O)OC1-C6 alkyl (preferably -C(O)OC1-C3 alkyl), -CONRiRii (wherein Ri and Rii are H, D and C1-C6 alkyl, preferably C1-C3 alkyl), -NHC(O)(C1-C6 alkyl), -NHC(O)(phenyl), -N(C1-C6 alkyl)C(O)(C1-C6 alkyl), -N(C1-C6 alkyl)C(O)(phenyl), -C(O)C1-C6 alkyl, -C(O)heteroaryl (preferably -C(O)-5-7 membered heteroaryl -C1-C6 alkyl), -C(O)2-C1-C6 alkylphenyl, -C(O)C1-C6 haloalkyl, -OC(O)C1-C6 alkyl (preferably -OC(O)C1-C3 alkyl), -S(O)2-C1-C6 alkyl, -S(O)-C1-C6 alkyl, -S(O)2-phenyl, -S(O)2-C1-C6 haloalkyl, -S(O)2NH2, -S(O)2NH(C1-C6 alkyl), -S(O)2NH(phenyl), -NHS(O)2(C1-C6 alkyl), -NHS(O)2(phenyl) and -NHS(O)2(C1-C6 haloalkyl),Each of the alkyl, cycloalkyl, phenyl, aryl, heterocyclyl and heteroaryl groups is optionally further substituted by one or more substituents selected from the following: halogen, -OH, -NH2, cycloalkyl, 3-8 membered heterocyclyl, C1-C4 alkyl, C1-C4 haloalkyl-, -OC1-C4 alkyl, -C1-C4 alkyl-OH, -C1-C4 alkyl-O-C1-C4 alkyl, -OC1-C4 haloalkyl, cyano, nitro, -C(O)-OH, -C(O)OC1-C6 alkyl, -CON(C1-C6 -C6 alkyl), -CONH(C1-C6 alkyl), -CONH2, -NHC(O)(C1-C6 alkyl), -NH(C1-C6 alkyl)C(O)(C1-C6 alkyl), -SO2(C1-C6 alkyl), -SO2(phenyl), -SO2(C1-C6 haloalkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2NH(phenyl), -NHSO2(C1-C6 alkyl), -NHSO2(phenyl) and -NHSO2(C1-C6 haloalkyl). When an atom or group is substituted with multiple substituents, the multiple substituents may be the same or different.

[0035] The term "hydrocarbon group" used in the present invention refers to the group remaining after an aliphatic hydrocarbon loses a hydrogen atom, including straight-chain or branched, saturated or unsaturated hydrocarbon groups, including alkyl, alkenyl and alkynyl groups, preferably the hydrocarbon group is C1-C 10 A hydrocarbon group, a C1-C6 hydrocarbon group, or a C1-C3 hydrocarbon group.

[0036] The term "alkyl" as used herein refers to a C1-C 24 Alkyl, C1-C 20 Alkyl, C1-C 18 Alkyl, C1-C 12 Alkyl, C1-C6 alkyl, C3-C 24 Alkyl, C3-C 20 Alkyl, C3-C 18 Alkyl, C3-C 12 Alkyl, C3-C6 alkyl, C6-C 24 Alkyl, C6-C 20 Alkyl, C6-C 18 Alkyl or C6-C 12 alkyl.

[0037] The term "alkenyl" as used herein refers to a C2-C 24 Alkenyl, C2-C 20 Alkenyl, C2-C 18 Alkenyl, C2-C 12 Alkenyl, C2-C6 alkenyl, C3-C 20 Alkenyl, C3-C18 Alkenyl, C3-C 12 Alkenyl, C3-C6 alkenyl, C6-C 24 Alkenyl, C6-C 20 Alkenyl, C6-C 18 Alkenyl or C6-C 12 Alkenyl.

[0038] The term "alkynyl" as used herein refers to a C2-C 24 Alkynyl, C2-C 20 Alkynyl, C2-C 18 Alkynyl, C2-C 12 Alkynyl, C2-C6 alkynyl, C3-C 20 Alkynyl, C3-C 18 Alkynyl, C3-C 12 Alkynyl, C3-C6 alkynyl, C6-C 24 Alkynyl, C6-C 20 Alkynyl, C6-C 18 Alkynyl or C6-C 12 Alkynyl.

[0039] The term "acyl" in the present invention means a hydrocarbon-carbonyl group, preferably a C4-C 24 Acyl, C6-C 18 Acyl, C6-C 12 Acyl, C6-C 10 Acyl, C4-C6 acyl.

[0040] The term "alkoxy" in the present invention means an alkyl-oxy group, preferably a C1-C 10 Alkoxy, more preferably, the alkoxy is C1-C6 alkoxy, most preferably, the alkoxy is C1-C3 alkoxy.

[0041] The term "heterocycle" in the present invention means a saturated or unsaturated cyclic group containing heteroatoms selected from N, O, S, etc. Preferably, the heterocycle is an optionally substituted 4- to 10-membered heterocycle containing 1 to 6 heteroatoms selected from N, O, S, or an optionally substituted 4- to 6-membered saturated heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, S. The heterocycle may be optionally substituted by one or more substituents, and the types of substituents refer to the above definition of "optionally substituted".

[0042] One embodiment of the present invention provides an amine lipid compound, which is a compound represented by the following Chemical Formula I:

[0043] [Chemical Formula I]

[0044]

[0045] In Formula I, R 1 and R 2 are the same as or different from each other and are each independently selected from C6-C 24 Alkyl, C6-C 24 Alkenyl, C6-C 24 Alkynyl and C4-C 24 Acyl, wherein the C6-C 24 Alkyl, the C6-C 24 Alkenyl, the C6-C 24 Alkynyl and the C4-C 24 The acyl group is optionally substituted with a C1-C6 hydrocarbon group;

[0046] Preferably, R 1 and R 2 are the same or different from each other and are each independently C6-C 18 alkyl.

[0047] X 1 , X 2 and X 3 are the same as or different from each other and are each independently selected from C, N, O, S, S=O, S(=O)2 and SS;

[0048] When X 1 When it is C, m=2, and two R 6 The same or different from each other; when X 1 When it is N, m=1; when X 1 When it is O, S, S=O, S(=O)2 or SS, m=0;

[0049] When X 2 When it is C, n=2, and two R 7 The same or different from each other; when X 2 When it is N, n=1; when X 2 When it is O, S, S=O, S(=O)2 or SS, n=0;

[0050] When X 3 When C, p = 2, and two R 8 The same or different from each other; when X 3 When it is N, p = 1; when X 3 When it is O, S, S=O, S(=O)2 or SS, p=0;

[0051] R 3 and R 4 are the same as or different from each other and are each independently selected from C1-C 12 Alkyl, C2-C 12 Alkenyl and C2-C 12Alkynyl, wherein the C1-C 12 Alkyl, the C2-C 12 Alkenyl and the C2-C 12 The alkynyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 combine with each other to form an optionally substituted 4- to 10-membered heterocyclic ring comprising 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen;

[0052] R 5 Does not exist, or R 5 is hydrogen or C1-C 12 Alkyl to provide a quaternary amine;

[0053] R 6 , R 7 , R 8 is hydrogen or C1-C 12 alkyl;

[0054] L is C1-C 12 Alkylene, C2-C 12 Alkenylene or C 2- C 12 Alkyne, wherein the C1-C 12 Alkylene, the C2-C 12 Alkenylene and the C2-C 12 The alkynylene group is optionally substituted with one or more substituents selected from hydrocarbyl, carboxyl, acyl and alkoxy, or L is an optionally substituted 4- to 10-membered heterocyclic ring containing a heteroatom selected from nitrogen, sulfur and oxygen.

[0055] Preferably, L is C1-C8 alkylene, C2-C6 alkylene, C2-C4 alkylene, or C3-C4 alkylene, wherein the C1-C8 alkylene, C2-C6 alkylene, C2-C4 alkylene, or C3-C4 alkylene is optionally substituted with a C1-C6 hydrocarbon group.

[0056] Specifically, another embodiment of the present invention provides an amino lipid compound, wherein in Chemical Formula I, X 1 C, R 6 is H, m = 2; or X 1 N, R 6 is H, m = 1; or X 1 is O, S, S=O, S(=O)2 or SS, m=0; X 2 C, R 7 is H, n = 2; or X 2 N, R 7 is H, n = 1; or X 2 For O, S, S=O, S(=O)2 or SS, n=0;3 C, R 8 is H, p = 2; or X 3 N, R 8 is H, p = 1; or X 3 It is O, S, S=O, S(=O)2 or SS, p=0.

[0057] More specifically, another embodiment of the present invention provides an amino lipid compound, wherein in Chemical Formula I, R 1 and R 2 are the same or different from each other and are each independently C6-C 24 Alkyl; X 1 N, R 6 is H, m = 1; or X 1 is S, m=0; X 2 N, R 7 is H, n = 1; or X 2 S, n = 0; X 3 N, R 8 H, p = 1; R 3 and R 4 are the same or different from each other and are each independently C 1- C 12 Alkyl, wherein the C 1- C 12 The alkyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 are combined with each other to form an optionally substituted 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen; R 5 Does not exist.

[0058] More specifically, according to another embodiment of the present invention, in Chemical Formula I, are the same as or different from each other and are each independently selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, 2 N 12 One of:

[0059] S6:CH3(CH2)5S-; S7:CH3(CH2)6S-; S8:CH3(CH2)7S-;

[0060] S9:CH3(CH2)8S-; S10:CH3(CH2)9S-; S11:CH3(CH2) 10 S-;

[0061] S12:CH3(CH2) 11 S-; S14:CH3(CH2) 13 S-; S15:CH3(CH2) 14 S-;

[0062] S16:CH3(CH2) 15 S-; S18:CH3(CH2) 17 S-;

[0063] N6:CH3(CH2)5NH-; N7:CH3(CH2)6NH-; N8:CH3(CH2)7NH-;

[0064] N9:CH3(CH2)8NH-; N11:CH3(CH2) 10 NH-; N12:CH3(CH2) 11 NH-;

[0065] N13:CH3(CH2) 12 NH-; N15:CH3(CH2) 14 NH-; N16:CH3(CH2) 15 NH-;

[0066] N18:CH3(CH2) 17 NH-; 2 N 12 :(CH3(CH2) 11 )2N-;

[0067] It is one selected from the following D1, D2, D3, D4, D5, D6, D7, D8, D9, D10:

[0068] D1: D2: D3: D4: D5: D6: D7: D8: D9: D10:

[0069] Another embodiment of the present invention provides a method for preparing an amino lipid compound, the method comprising the following steps: (1) reacting cyanuric chloride with R at a temperature of -30°C to 30°C in the presence of a base as an acid-binding agent; 1 -X 1 The compound represented by H is subjected to a first reaction to obtain a first intermediate, wherein X 1is NH or S; (2) without isolating the first intermediate, adding R 2 -X 2 The compound represented by H is subjected to a second reaction in the presence of a base as an acid-binding agent to obtain a second intermediate, wherein X 2 is NH or S; (3) without isolating the second intermediate, adding H2N-(CH2)q-NR 3 R 4 The diamine represented by is subjected to a third reaction under heating conditions to obtain an amino lipid compound; wherein q is an integer from 1 to 12, R 1 , R 2 , R 3 and R 4 The definition of is the same as that in the above description of the amino lipid compound.

[0070] Preferably, the first reaction is carried out at a temperature below 20°C, below 15°C, below 10°C, below 5°C, below 0°C, below -10°C or below -20°C, and there is no specific restriction on the lower limit of the reaction temperature, specifically, above -40°C, above -35°C, above -30°C.

[0071] The “room temperature” is the usual temperature under atmospheric pressure, and may refer to a temperature range of 0°C to 30°C, 0°C to 25°C, 0°C to 20°C, 5°C to 30°C, 5°C to 20°C, 10°C to 30°C, 10°C to 25°C, 15°C to 30°C, and 15°C to 25°C.

[0072] The “heating conditions” specifically refer to heating to a temperature range of 50°C to 120°C, 50°C to 110°C, 50°C to 80°C, 60°C to 120°C, 60°C to 110°C, 60°C to 100°C, 70°C to 120°C, 70°C to 100°C, and 70°C to 90°C.

[0073] The "base" may specifically be a base compound commonly used in the art, specifically, an organic base such as triethylamine, DIPEA, pyridine, DMAP, or an inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate.

[0074] Preferably, q is an integer of 1-8, more preferably, q is an integer of 1-6, and more preferably, q is an integer of 1-4.

[0075] More specifically, the preparation method of the amino lipid compound according to one embodiment of the present invention can be carried out by the following reaction formula 1:

[0076] [Reaction 1]

[0077]

[0078] Among them, R 1 , R 2 , R 3 , R 4 , X 2 The definition of is the same as that in the above description of the preparation method of the amino lipid compound.

[0079] More specifically, the preparation method of the amino lipid compound according to another embodiment of the present invention can be carried out by the following reaction formula 2:

[0080] [Reaction 2]

[0081]

[0082] Among them, R 1 , R 2 , R 3 , R 4 , X 2 The definition of is the same as that in the above description of the preparation method of the amino lipid compound.

[0083] It can be seen that the method for preparing the amino lipid compound according to the present invention is very versatile and can be used for the rapid synthesis of a cationic amino lipid compound library and for rapid cell-based screening experiments in a very inexpensive manner.

[0084] Another embodiment of the present invention relates to lipid particles containing the aforementioned amine lipid compounds. Because the amine lipid compounds of the present invention contain long non-polar residues, the resulting compounds all have hydrophobic characteristics and, due to the amino group, have hydrophilic characteristics at the same time. This amphiphilic characteristic can be used to form lipid particles, for example, lipid bilayers, micelles, liposomes, etc.

[0085] In the context of the present invention, the term "lipid particles" means nanosized substances obtained by placing amino lipid compounds in aqueous solution, these particles are in particular lipid bilayer vesicles (liposomes), multilamellar vesicles or micelles.

[0086] In a preferred embodiment of the present invention, the lipid particles are liposomes containing the aforementioned amino lipid compounds. Within the scope of the present invention, liposomes are microvesicles consisting of a bilayer of lipid amphiphilic molecules enclosing an aqueous compartment.

[0087] Liposome formation is not a spontaneous process. Lipid vesicles are first formed when lipids are placed in water, thus forming a bilayer or a series of bilayers, each separated by water molecules. Liposomes can be formed by ultrasonicating lipid vesicles in water.

[0088] In the context of the present invention, the term "lipid bilayer" means a thin film formed by two layers of lipid molecules. The term "micelle" means an aggregate of surfactant molecules dispersed in a liquid colloid. Typical micelles in aqueous solutions form aggregates when exposed to water with the hydrophilic head region sequestering the hydrophobic single tail region in the center of the micelle.

[0089] In the context of the present invention, the term "cell" is meant as a general term and includes cultures of single cells, tissues, organs, insect cells, avian cells, fish cells, amphibian cells, mammalian cells, primary cells, continuous cell lines, stem cells and / or genetically engineered cells (e.g., recombinant cells expressing heterologous polypeptides or proteins). Recombinant cells include, for example, cells expressing heterologous polypeptides or proteins (e.g., growth factors or blood factors).

[0090] In a preferred embodiment, the lipid granule or liposome further contains a helper lipid. In a preferred embodiment, the helper lipid is a non-cationic lipid. In a more preferred embodiment, the helper lipid is a non-cationic phospholipid. Within the scope of the present invention, the non-cationic lipid can contain a cationic functional group (e.g., an ammonium group), but should contain an anionic functional group to at least neutralize the molecule. The totality of all functional groups in the lipid molecule should be non-cationic. The liposome composed of a mixture of cationic amine lipids and non-cationic (neutral) phospholipids is the most effective for nucleic acid to be delivered to the cell. In an even more preferred embodiment, the non-cationic lipid is DOPE.

[0091] In a further preferred embodiment, the lipid particles or liposomes further comprise a sterol. Sterols, such as cholesterol, are natural components of cell membranes. They can be used to stabilize the particles and help integrate with the cell membrane.

[0092] In another embodiment of the present invention, lipid granule or liposome further contain bioactivator.Within the scope of the present invention, bioactivator is the material with biological action when being introduced in cell or host, for example, by stimulating immune response or inflammatory response, by exerting enzymatic activity or by supplementing sudden change etc. to work, bioactivator particularly nucleic acid, peptide, albumen, antibody and small molecule.When liposome is used for medicine being wrapped in lipid bilayer or in the internal water-containing space of liposome, term " lipid granule medicine " can be used.

[0093] In the most preferred embodiment, the bioactive agent is a nucleic acid. In another preferred embodiment, the bioactive agent is a member selected from an anti-tumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, a polypeptide or a member of a class of polypeptides (polypeptoids).

[0094] In another embodiment, lipid granule or liposome further contain at least one polyethylene glycol (PEG)-lipid.PEG lipid helps to protect granule and its inclusion from external or internal degradation.In addition, PEG forms a protective layer on the liposome surface, and improves the internal circulation time.It can be used for liposome drug delivery (PEG-liposome).

[0095] Lipid particles or liposomes containing a biologically active agent can be used to deliver any of a variety of therapeutic agents into cells. The present invention includes the use of lipid particles, especially liposomes, as described above for delivering a biologically active agent into a cell.

[0096] Preferably, the bioactive agent is a nucleic acid, including but not limited to messenger RNA (mRNA), antisense oligonucleotides, DNA, plasmids, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA) and small nuclear RNA (snRNA). The bioactive agent can also be an anti-tumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or its fragment, a protein, a peptide, a polypeptide, a vaccine and a small molecule, or a mixture thereof. As shown above, lipid particles or liposomes containing the amino lipid compounds defined in the present invention are suitable for delivering the bioactive agent to cells. The specific characteristics of the liposomes given to the various different amino lipid compounds synthesized by the general synthetic method can be screened. Important features are, for example, transfection efficiency, cytotoxicity, adhesion of the agent to be delivered to the cell, stability of the liposomes, size of the liposomes, etc. The method of the present invention can form specifically adapted liposomes for specific applications.

[0097] For example, lipid particles or liposomes can be used to transfect multiple cellular tissues or organs. This provides new therapeutic treatment possibilities for patients.

[0098] According to the present invention, the patient can be any mammal, preferably selected from humans, mice, rats, pigs, cats, dogs, horses, goats, cows and monkeys and / or others. Most preferably, the patient is a human.

[0099] An important embodiment of the present invention is the use of the lipid particles or liposomes containing the amino lipid compound according to one of the general formulae (I-III) as a medicament.

[0100] In particular, the lipid particles or liposomes can be administered to patients for gene therapy, gene vaccination, antisense therapy or treatment by interfering RNA. Specific application areas include but are not limited to:

[0101] (1) The lipid particles of the present invention can deliver nucleic acids for gene therapy. The amino lipids of the present invention are used to introduce exogenous genes into target cells to correct or compensate for diseases caused by defective and abnormal genes to achieve the purpose of treatment. This also includes technical applications in transgenics, that is, inserting exogenous genes into appropriate recipient cells of patients through gene transfer technology so that the products produced by exogenous genes can treat certain diseases, such as common lung cancer, gastric cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphoma, blood cancer, prostate cancer, etc. Gene-edited nucleic acid substances can also be introduced for the treatment of various genetic diseases, such as hemophilia, thalassemia, Gaucher's disease, etc.

[0102] (2) The lipid particles of the present invention can be used in vaccination. The lipid particles or liposomes of the present invention can be used to deliver antigens or nucleic acids encoding antigens. The lipid particles of the present invention can also be used to elicit immune responses against various antigens that are used to treat and / or prevent a variety of conditions, such as cancer, allergies, toxicity, and infection with pathogens (e.g., viruses, bacteria, fungi, and other pathogenic organisms).

[0103] The above-mentioned lipid particles can be used to prepare drugs for nucleic acid transfer, preferably, the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA) and small nuclear RNA (snRNA).

[0104] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described in combination with specific embodiments below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0105] Example 1: Synthesis of amino lipid compounds

[0106] In order to systematically study the relationship between the length of alkyl chain, the combination of alkyl chain, cationic head group and transfection ability, 11 linear alkylthiols (S6-S18) with 6-18 carbon chains, 11 alkylamines (N6- 2 N12), 10 diamines with different structures (D1-D6). Using combinatorial chemistry methods, a library of 2530 compounds containing two alkyl chains and cationic head groups was synthesized in high throughput. The synthesis path is as follows:

[0107] (a) Triazine as a linking group

[0108]

[0109] (b) Typical Examples

[0110]

[0111] (c) Synthetic building blocks

[0112]

[0113] (d) Compound library

[0114]

[0115] Example 1.1: Parallel synthesis and characterization of the S8NxDy series of amino lipid compound libraries

[0116]

[0117] Add cyanuric chloride (2mmol) and THF (10mL) to a 50mL dry reaction bottle, stir in a cold bath and cool to -20°C, then add 1-octanethiol (2mmol) and DIPEA (2.4mmol) in sequence. A large amount of precipitate will precipitate out immediately in the reaction solution. After 5 minutes of reaction, the reaction is completed by TLC detection. Transfer the reaction solution to a 15mL centrifuge tube, make the volume to 15mL, and centrifuge in a centrifuge (2000r / min, 1min). Obtain Step I reaction solution (15mL, 0.13M).

[0118] Use a pipette to transfer the Step I reaction solution to 11 1.5 mL reaction bottles (1.15 mL, 0.15 mmol each). Add linear alkylamine (0.15 mmol) and DIPEA THF solution (0.35 mL, 0.5 M) to the corresponding reaction bottles. Stir the reaction at room temperature for 2 h. TLC detection shows that there is no Step I raw material.

[0119] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (0.1 mL, 0.01 mmol each) using a pipette, and a THF solution of diamine (0.12 mL, 0.012 mmol, 0.1 M) and a THF solution of DIPEA (0.02 mL, 0.1 M) were added to the corresponding reaction tubes, and the mixture was reacted at 78 ° C for 1 h in a heated shaking reactor (Thermo-Shaker). TLC detected that there was no Step II raw material. After the reaction was completed, the solvent in the reaction tube was evaporated at room temperature to obtain 110 amino lipid compounds S8NxDy. Ten representative compounds were selected for mass spectrometry detection, and the results are shown in Table 1 below.

[0120] Table 1 MW / z values ​​of representative compounds

[0121]

[0122]

[0123] Example 1.1.1: One-pot synthesis and characterization of a representative amino lipid compound S8N11D6.

[0124]

[0125] Add cyanuric chloride (1mmol) and THF (10mL) to a 20mL dry reaction tube, stir in a cold bath and cool to -20°C, then add 1-octanethiol (1mmol) and DIPEA (1.2mmol) in sequence, a large amount of precipitate will precipitate out of the reaction solution immediately, and the reaction is completed by TLC detection after 5min of reaction. After the reaction solution is warmed to room temperature, undecylamine (1mmol) and DIPEA (1.2mol) are added, and the reaction is stirred at room temperature for 2h. TLC detection shows that there is no Step I raw material. Then add N,N-dimethylpropylenediamine (1.2mmol) and DIPEA (2mol) and stir and heat to 78°C for 1h. TLC detection shows that there is no Step II raw material. Purify using an automatic purification system (forward silica gel column, DCM:MeOH gradient elution from 0 to 10%) to obtain 440.4mg of white solid, with a three-step reaction yield of 89% and a purity of >99%. 1 H NMR (400MHz, CDCl3) δ3.54(m,2H),3.34(m,2H),3.01(m,4H),2.80-2.73(m,6H),2.07(m,2H), 1.67(m,2H),1.53(m,2H),1.38(m,2H),1.28(m,2H),1.24(m,24H),0.88-0.84(m,6H).ESI-MS calculated for C27H55N6S+[M+H]+495.4, found 495.6.

[0126] Example 1.2: Parallel synthesis and characterization of the S6SxDy series of amino lipid compound libraries

[0127]

[0128] Add cyanuric chloride (2mmol) and THF (10mL) to a 50mL dry reaction bottle, stir in a cold bath and cool to -20°C, then add 1-hexanethiol (2mmol) and DIPEA (2.4mmol) in sequence. A large amount of precipitate will precipitate out immediately in the reaction solution. After 5 minutes of reaction, the reaction is completed by TLC detection. Transfer the reaction solution to a 15mL centrifuge tube, make the volume to 15mL, and centrifuge in a centrifuge (2000r / min, 1min). Obtain Step I reaction solution (15mL, 0.13M).

[0129] The reaction solution of step I was transferred to 11 1.5 mL reaction bottles (1.15 mL, 0.15 mmol each) using a pipette, and linear alkyl thiol (0.15 mmol) and DIPEA THF solution (0.35 mL, 0.5 M) were added to the corresponding reaction bottles. The reaction was stirred at room temperature for 2 h. TLC detection showed that there was no Step I starting material.

[0130] Each Step II reaction solution was transferred to 10 1.5mL EP tubes (0.1mL, 0.01mmol each) using a pipette, and a THF solution of diamine (0.12mL, 0.012mmol, 0.1M) and a THF solution of DIPEA (0.02mL, 0.1M) were added to the corresponding reaction tubes, and the mixture was reacted at 78°C for 1h in a heated shaking reactor (Thermo-Shaker). TLC detected that there was no Step II raw material. After the reaction, the solvent in the reaction tube was evaporated at room temperature to obtain 110 amino lipid compounds S6SxDy. Ten representative compounds were selected for mass spectrometry detection, and the results are shown in Table 2 below.

[0131] Table 2 MW / z values ​​of representative compounds

[0132]

[0133]

[0134]

[0135] Example 1.2.1: One-pot synthesis and characterization of a representative amino lipid compound S6S11D6

[0136]

[0137] Add cyanuric chloride (1mmol) and THF (10mL) to a 20mL dry reaction tube, stir in a cold bath and cool to -20°C, then add 1-hexanethiol (1mmol) and DIPEA (1.2mmol) in sequence, a large amount of precipitate will precipitate out of the reaction solution immediately, and the reaction is completed by TLC detection after 5min of reaction. After the reaction solution is warmed to room temperature, undecanethiol (1mmol) and DIPEA (1.2mol) are added, and the reaction is stirred at room temperature for 2h. TLC detection shows that there is no Step I raw material. Then add N,N-dimethylpropylenediamine (1.2mmol) and DIPEA (2mol) and stir and heat to 78°C for 1h. TLC detection shows that there is no Step II raw material. Purify using an automatic purification system (forward silica gel column, DCM:MeOH gradient elution from 0 to 10%) to obtain 445.1mg of white solid, with a three-step reaction yield of 92% and a purity of 99%. 1 HNMR(400MHz, CDCl3)δ3.51(m,2H),3.04-3.01(m,4H),2.81-2.74(m,6H),2.09(m,2H),1.68(m, 2H),1.55(m,2H),1.33(m,2H),1.29(m,2H),1.23(m,22H),0.88-0.84(m,6H).ESI-MScalculated for C 25 H 50 N5S2 + [M+H] + 484.4, found 484.4.

[0138] Example 1.3: Parallel synthesis and characterization of the N6NxDy series of amine lipid compound libraries

[0139]

[0140] Add cyanuric chloride (2mmol) and THF (10mL) to a 50mL dry reaction bottle, stir in a cold bath and cool to -20°C, then add 1-hexylamine (2mmol) and DIPEA (2.4mmol) in sequence. A large amount of precipitate will precipitate out immediately in the reaction solution. After 5 minutes of reaction, the reaction is complete by TLC detection. Transfer the reaction solution to a 15mL centrifuge tube, make the volume to 15mL, and centrifuge in a centrifuge (2000r / min, 1min). Obtain Step I reaction solution (15mL, 0.13M).

[0141] Use a pipette to transfer the Step I reaction solution to 11 1.5 mL reaction bottles (1.15 mL, 0.15 mmol each). Add linear alkyl (0.15 mmol) and DIPEA THF solution (0.35 mL, 0.5 M) to the corresponding reaction bottles. Stir the reaction at room temperature for 2 h. TLC detection shows that there is no Step I raw material.

[0142] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (0.1 mL, 0.01 mmol each) using a pipette, and a THF solution of diamine (0.12 mL, 0.012 mmol, 0.1 M) and a THF solution of DIPEA (0.02 mL, 0.1 M) were added to the corresponding reaction tubes, and the mixture was reacted at 78 ° C for 1 h in a heated shaking reactor (Thermo-Shaker). TLC detected that there was no Step II raw material. After the reaction was completed, the solvent in the reaction tube was evaporated at room temperature to obtain 110 amino lipid compounds N6NxDy. Ten representative compounds were selected for mass spectrometry detection, and the results are shown in Table 3.

[0143] Table 3 MW / z values ​​of representative compounds

[0144]

[0145]

[0146] Example 1.3.1: One-pot synthesis and characterization of a representative amino lipid compound N6N11D6

[0147]

[0148] Add cyanuric chloride (1mmol) and THF (10mL) to a 20mL dry reaction tube, stir in a cold bath and cool to -20°C, then add 1-hexylamine (1mmol) and DIPEA (1.2mmol) in sequence, a large amount of precipitate will precipitate out of the reaction solution immediately, and the reaction is completed by TLC detection after 5min of reaction. After the reaction solution is warmed to room temperature, undecylamine (1mmol) and DIPEA (1.2mol) are added, and the reaction is stirred at room temperature for 2h. TLC detection shows that there is no Step I raw material. Then add N,N-dimethylpropylenediamine (1.2mmol) and DIPEA (2mol) and heat to 78°C for 1h under stirring. TLC detection shows that there is no Step II raw material. Purify using an automatic purification system (forward silica gel column, DCM:MeOH gradient elution from 0 to 10%) to obtain 395.7mg of white solid, with a three-step reaction yield of 88% and a purity of 99%. 1H NMR (400MHz, CDCl3) δ3.54(m,2H),3.05-3.02(m,4H),2.82-2.73(m,6H),2.08(m,2H),1.69(m,2 H),1.54(m,2H),1.34(m,2H),1.30(m,2H),1.24(m,22H),0.89-0.85(m,6H).ESI-MScalculated for C 25 H 52 N7 + [M+H] + 450.4, found 450.4.

[0149] Example 2: Preliminary screening of amino lipid compounds as DNA carriers

[0150] Cell line: HEK293 cells

[0151] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0152] Screening format: 96-well plate cell transfection

[0153] Detection (readout): relative to total cell number (total cell number is determined using the nuclear dye Hoechst - see Figure 1 ) The percentage of GFP fluorescent cells. Lipofectamine 2000 was used as a positive control group according to the manufacturer's instructions.

[0154] Method: Use an 8-channel pipette for loading. Contents shown are for a single well of a 96-well plate.

[0155] 1. The compound (0.01 mmol) prepared in Example 1 was dissolved in 1 mL of anhydrous ethanol. After ultrasonic dissolution, 10 μL was taken out and mixed with 5 μL of DOPE ethanol solution (0.01 M), and 35 μL of 0.2 M sodium acetate buffer (pH 5.6) was added to the mixture, and constant vortexing was used for 30 s to prepare 50 μL of solution. Then 4 μL was taken out from the 50 μL liposome solution and added to 46 μL of 0.02 M sodium acetate buffer (pH 5.6), and constant vortexing was used for 30 s to form the final liposome. 5 μL was taken out from the above final liposome and mixed with 75 ng of plasmid DNA (pSin-EGFP-IRES-Puro) dissolved in 5 μL of 0.02 M sodium acetate buffer, and placed at room temperature for 30 min to form a lipid / DNA transfection complex.

[0156] 2. After incubating 10 μL of lipid / DNA transfection complex at room temperature for 30 min, add 90 μL of freshly resuspended cells (3-5×10 4100 μL of cells+lipid / DNA complexes were immediately transferred to separate wells of a 96-well culture plate and placed in an incubator at 37°C containing 5% CO2.

[0157] 3. 20 to 24 hours after the initial transfection of cells, add Hoechst33258 to the cells at a final concentration of 0.2 μg / ml and culture them at 37°C in the dark for 15 minutes. Then wash the cells once with PBS solution and add culture medium to culture for 20 to 24 hours.

[0158] 4. Place the cells in a high-throughput confocal microscope (Molecular Devices ImageXpress) and capture 4 images of the cells from each well. For each sample, capture 3 laser wavelength images: bright field image of the cells ( Figure 1 (a) and Figure 1 (b)), Hoechst staining image showing total cell nuclei ( Figure 1 (c) and Figure 1 (d)) and GFP images showing successful transfection with plasmid DNA and expression of GFP ( Figure 1 (e) and Figure 1 (f)). MetaXpress software was used to count the cells in the Hoechst staining image and GFP image, and then the number of cells expressing GFP was divided by the total number of cell nuclei to obtain the absolute transfection efficiency of the cells. The absolute transfection efficiency was calculated as follows:

[0159]

[0160] Results: The transfection efficiency of 2530 compounds on the DNA of HEK293 cells is shown in Table 4.

[0161] Table 4 Absolute transfection efficiency of 2530 compounds on DNA of HEK293 cells.

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169] Example 3: Preliminary screening of amino lipid compounds as mRNA carriers

[0170] Cell line: HEK293 cells

[0171] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0172] Screening format: 96-well plate cell transfection

[0173] Detection (readout): percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine 2000 was used as a positive control.

[0174] Method: The experimental method was basically the same as that in Example 2, and the mass of transfected EGFP mRNA was 50 ng per well.

[0175] Results: The absolute transfection efficiency of 2530 compounds on mRNA of HEK293 cells is shown in Table 5.

[0176] Table 5 Absolute transfection efficiency of 2530 compounds on mRNA of HEK293 cells

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184] Example 4: Transfection of Hela cell line using amino lipid compounds as DNA vectors

[0185] Cell line: HeLa cells

[0186] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0187] Screening format: 96-well plate cell transfection

[0188] Detection (readout): percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine 2000 was used as a positive control according to the manufacturer's instructions.

[0189] Method: The experimental method is basically the same as that in Example 2.

[0190] Results: The absolute transfection efficiency of 170 compounds on Hela cells is shown in Table 6.

[0191] Table 6 Absolute DNA transfection efficiency of 170 compounds on Hela cells

[0192]

[0193] Example 5: Transfection of Hela cells using amino lipid compounds as mRNA carriers

[0194] Cell line: HeLa cells

[0195] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0196] Screening format: 96-well plate cell transfection

[0197] Detection (readout): percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Commercially available liposomal transfection reagent Lipofectamine 2000 was used as a positive control according to the manufacturer's instructions.

[0198] Method: The experimental method was basically the same as that in Example 2, and the mass of transfected EGFP mRNA was 50 ng per well.

[0199] Results: The absolute transfection efficiency of 170 compounds on Hela cell mRNA is shown in Table 7.

[0200] Table 7 Absolute transfection efficiency of 170 compounds on mRNA of Hela cells

[0201]

[0202] Example 6: Transfection of MCF7 Cell Line Using Amino Lipid Compounds as DNA Vectors

[0203] Cell line: MCF7 cells

[0204] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0205] Screening format: 96-well plate cell transfection

[0206] Detection (readout): percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine 2000 was used as a positive control according to the manufacturer's instructions.

[0207] Method: The experimental method is basically the same as that in Example 2.

[0208] Results: The absolute DNA transfection efficiency of the 102 compounds on MCF7 cells is shown in Table 8.

[0209] Table 8 Absolute DNA transfection efficiency of 102 compounds on MCF7 cells

[0210]

[0211] Example 7: Transfection of MCF7 Cell Line Using Amino Lipid Compounds as mRNA Carriers

[0212] Cell line: MCF7 cells

[0213] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0214] Screening format: 96-well plate cell transfection

[0215] Detection (readout): percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine 2000 was used as a positive control.

[0216] Method: The experimental method was basically the same as that in Example 2, and the mass of transfected EGFP mRNA was 50 ng per well.

[0217] Results: The absolute transfection efficiency of 102 compounds on mRNA of MCF7 cells is shown in Table 9.

[0218] Table 9 Absolute transfection efficiency of 102 compounds on mRNA of MCF7 cells

[0219]

[0220] Example 8: Screening of amino lipid compounds as DNA vectors in difficult-to-transfect cell lines (embryonic stem cells)

[0221] Cell line: Embryonic stem cells

[0222] Culture medium: mTeSR1 (STEMCELL)

[0223] Screening format: 96-well plate cell transfection

[0224] Detection (readout): percentage of GFP fluorescent cells relative to total cell number. Lipofectamine Stem was used as a positive control.

[0225] Method: Use an 8-channel pipette for loading. Contents shown are for a single well of a 96-well plate.

[0226] 1. Culture stem cells in a 96-well plate treated with matrix gel to 3-5 × 10 cells per well. 4 cell.

[0227] 2. The compound (0.01 mmol) prepared in Example 1 was dissolved in 1 mL of anhydrous ethanol. After ultrasonic dissolution, 10 μL and 5 μL of DOPE ethanol solution (0.01 M) were mixed, and 35 μL of 0.2 M sodium acetate buffer (pH 5.6) was added to the mixture, and constant vortexing was used for 30 s. Then 4 μL was taken out from it and added to 46 μL of 0.02 M sodium acetate buffer (pH 5.6), and constant vortexing was used for 30 s to form liposomes. 5 μL of the above lipid reagent was mixed with 75 ng of plasmid DNA (pSin-EGFP-IRES-Puro) dissolved in 5 μL of 0.02 M sodium acetate buffer, and placed at room temperature for 30 min to form a lipid / DNA transfection complex.

[0228] 3. After incubating 10 μL of lipid / DNA transfection complex at room temperature for 30 min, add 90 μL of mTeSR1 medium and mix with a pipette. Add 100 μL of the mixture to separate wells of a 96-well culture plate and place in a 37°C incubator containing 5% CO2.

[0229] 4. 48 hours after cell transfection, digest the cells with 0.05% Trypsin-EDTA, resuspend the cells in PBS buffer, and filter. Place the cell suspension in a flow cytometer and measure the number of cells expressing GFP in no less than 2000 cells to obtain the absolute efficiency of cell transfection. Compare the cell transfection efficiency with the positive control group Lipofectamine Stem to obtain the relative efficiency of cell transfection.

[0230] Results: The absolute DNA transfection efficiencies of the 60 compounds on embryonic stem cells are shown in Table 10.

[0231] Table 10 Absolute DNA transfection efficiency of 60 compounds on embryonic stem cells

[0232]

[0233] Example 9: Screening of amino lipid compounds as mRNA carriers in difficult-to-transfect cell lines (embryonic stem cells)

[0234] Cell line: Embryonic stem cells

[0235] Culture medium: mTeSR1 (STEMCELL)

[0236] Screening format: 96-well plate cell transfection

[0237] Detection (readout): percentage of GFP fluorescent cells relative to total cell number. Lipofectamine Stem was used as a positive control.

[0238] Method: The experimental method was basically the same as that in Example 8, and the mass of transfected EGFP mRNA was 50 ng per well.

[0239] Results: The absolute mRNA transfection efficiency of the 60 compounds on embryonic stem cells is shown in Table 11.

[0240] Table 11 Absolute transfection efficiency of 60 compounds on mRNA of embryonic stem cells

[0241]

[0242] Example 10: Screening of amino lipid compounds as DNA vectors in difficult-to-transfect cell lines (cardiomyocytes)

[0243] Cell line: Cardiomyocytes

[0244] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0245] Screening format: 96-well plate cell transfection

[0246] Detection (readout): Percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine Stem was used as a positive control according to the manufacturer's instructions.

[0247] Method: The experimental method is basically the same as that in Example 2.

[0248] Results: The absolute DNA transfection efficiency of the 60 compounds on cardiomyocytes is shown in Table 12.

[0249] Table 12 Absolute DNA transfection efficiency of 60 compounds on cardiomyocytes

[0250]

[0251] Example 11: Screening of amino lipid compounds as mRNA carriers in difficult-to-transfect cell lines (cardiomyocytes)

[0252] Cell line: Cardiomyocytes

[0253] Culture medium: DMEM supplemented with 10% fetal bovine serum

[0254] Screening format: 96-well plate cell transfection

[0255] Detection (readout): Percentage of GFP fluorescent cells relative to total cell number (total cell number was determined using the nuclear dye Hoechst). Lipofectamine Stem was used as a positive control according to the manufacturer's instructions.

[0256] Method: The experimental method was basically the same as that in Example 2, and the mass of transfected EGFP mRNA was 50 ng per well.

[0257] Results: The absolute transfection efficiency of 60 compounds on cardiomyocyte mRNA is shown in Table 13.

[0258] Table 13 Absolute transfection efficiency of 60 compounds on mRNA of cardiomyocytes

[0259]

[0260] List of abbreviations

[0261] DMEM basal high glucose medium

[0262] DNA deoxyribonucleic acid

[0263] DOPE Dioleoylphosphatidylethanolamine GFP Green Fluorescent Protein

[0264] EGFP-enhanced GFP kD kilodaltons

[0265] RNA Ribonucleic acid

[0266] THF Tetrahydrofuran

[0267] DIPEA N,N-Diisopropylethylamine.

Claims

1. An amine lipid compound, which is a compound represented by the following chemical formula I: [Chemical Formula I] In Formula I, R 1 and R 2 are the same as or different from each other and are each independently selected from C6-C 24 Alkyl, C6-C 24 Alkenyl, C6-C 24 Alkynyl and C4-C 24 Acyl, wherein The C6-C 24 Alkyl, the C6-C 24 Alkenyl, the C6-C 24 Alkynyl and the C4-C 24 The acyl group is optionally substituted with a C1-C6 hydrocarbon group; X 1 is selected from the group consisting of C, O, S, S=O, S(=O)2 and SS; X 2 and X 3 are the same as or different from each other and are each independently selected from C, N, O, S, S=O, S(=O)2 and SS; When X 1 When it is C, m=2, and two R 6 The same or different from each other; when X 1 When it is O, S, S=O, S(=O)2 or SS, m=0; When X 2 When it is C, n=2, and two R 7 The same or different from each other; when X 2 When it is N, n=1; when X 2 When it is O, S, S=O, S(=O)2 or SS, n=0; When X 3 When it is C, p = 2, and the two R 8 The same or different from each other; when X 3 When it is N, p = 1; when X 3 When it is O, S, S=O, S(=O)2 or SS, p=0; R 3 and R 4 are the same as or different from each other and are each independently selected from C1-C 12 Alkyl, C2-C 12 Alkenyl and C2-C 12 Alkynyl, wherein the C1-C 12 Alkyl, the C2-C 12 Alkenyl and the C2-C 12 The alkynyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 Combined with each other to form a 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen, wherein the 4- to 10-membered heterocyclic ring is optionally substituted with a C1-C3 alkyl group; R 5 Does not exist, or R 5 is hydrogen or C1-C 12 Alkyl to provide a quaternary amine; R 6 , R 7 , R 8 is hydrogen or C1-C 12 alkyl; L is C1-C 12 Alkylene, wherein the C1-C 12 The alkylene group is optionally substituted with one or more substituents selected from the group consisting of a hydrocarbyl group, a carboxyl group, an acyl group, and an alkoxy group.

2. The amino lipid compound according to claim 1, wherein X 1 C, R 6 is H, m = 2; or X 1 is O, S, S=O, S(=O)2 or SS, m=0; X 2 C, R 7 is H, n = 2; or X 2 N, R 7 is H, n = 1; or X 2 For O, S, S=O, S(=O)2 or SS, n=0; X 3 C, R 8 is H, p = 2; or X 3 N, R 8 is H, p = 1; or X 3 For O, S, S=O, S(=O)2 or SS, p=0.

3. The amino lipid compound according to claim 1, wherein X 2 N or S; When X 1 When it is S, m=0; When X 2 When it is N, n=1; when X 2 When S, n=0; and / or X 3 N and p = 1, or X 3 is O and p=0; and / or R 5 does not exist; and / or L is C1-C 12 Alkylene, the C1-C 12 The alkylene group is optionally substituted with a C1-C6 hydrocarbon group.

4. The amino lipid compound according to claim 1, wherein R 1 and R 2 are the same or different from each other and are each independently C6-C 24 alkyl; X 1 is S, m=0; X 2 N, R 7 is H, n = 1; or X 2 is S, n = 0; X 3 N, R 8 is H, p = 1; R 3 and R 4 are the same or different from each other and are each independently C 1- C 12 Alkyl, wherein the C 1- C 12 The alkyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 Combined with each other to form a 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen, wherein the 4- to 10-membered heterocyclic ring is optionally substituted with a C1-C3 alkyl group; R 5 Does not exist.

5. The amino lipid compound according to any one of claims 1 to 4, wherein X 1 For S, X 2 N, X 3 is N.

6. The amino lipid compound according to any one of claims 1 to 4, wherein X 1 For S, X 2 For S, X 3 is N.

7. The amino lipid compound according to any one of claims 1 to 4, wherein L is a C1-C4 alkylene group, wherein the C1-C4 alkylene group is optionally substituted by a C1-C6 hydrocarbon group.

8. The amino lipid compound according to any one of claims 1 to 4, wherein R 1 and R 2 are the same or different from each other and are each independently C6-C 18 alkyl.

9. The amino lipid compound according to claim 1, wherein is one selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18; is selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, 2 N 12 One of: S6:CH3(CH2)5S-; S7:CH3(CH2)6S-; S8:CH3(CH2)7S-; S9:CH3(CH2)8S-;S10:CH3(CH2)9S-;S11:CH3(CH2) 10 S-; S12:CH3(CH2) 11 S-;S14:CH3(CH2) 13 S-;S15:CH3(CH2) 14 S-; S16:CH3(CH2) 15 S-;S18:CH3(CH2) 17 S-; N6:CH3(CH2)5NH-; N7:CH3(CH2)6NH-; N8:CH3(CH2)7NH-; <h2 style=";text-align:left;direction:ltr">N9:CH3(CH2)8NH-;N11:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> NH-;N12:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> NH-; N13:CH3(CH2) 12 NH-;N15:CH3(CH2) 14 NH-;N16:CH3(CH2) 15 NH-; <h2 style=";text-align:left;direction:ltr">N18:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 17 <h2 style=";text-align:left;direction:ltr"> NH-;<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> N<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> :(CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> )2N-; It is one selected from the following D1, D2, D3, D4, D5, D6, D7, D8, D9: D1: D2: D3: D4: D5: D6: D7: D8: D9:

10. An amine lipid compound, which is a compound represented by the following Chemical Formula I: [Chemical Formula I] in, is one selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18; is selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, 2 N 12 One of: S6:CH3(CH2)5S-; S7:CH3(CH2)6S-; S8:CH3(CH2)7S-; S9:CH3(CH2)8S-;S10:CH3(CH2)9S-;S11:CH3(CH2) 10 S-; S12:CH3(CH2) 11 S-;S14:CH3(CH2) 13 S-;S15:CH3(CH2) 14 S-; S16:CH3(CH2) 15 S-;S18:CH3(CH2) 17 S-; N6:CH3(CH2)5NH-; N7:CH3(CH2)6NH-; N8:CH3(CH2)7NH-; <h2 style=";text-align:left;direction:ltr">N9:CH3(CH2)8NH-;N11:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> NH-;N12:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> NH-; N13:CH3(CH2) 12 NH-;N15:CH3(CH2) 14 NH-;N16:CH3(CH2) 15 NH-; <h2 style=";text-align:left;direction:ltr">N18:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 17 <h2 style=";text-align:left;direction:ltr"> NH-;<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> N<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> :(CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> )2N-; It is D10: D10: 11. A method for preparing the amino lipid compound according to any one of claims 1 to 9, the method comprising the following steps: (1) At a temperature of -30°C to 30°C, in the presence of a base as an acid-binding agent, cyanuric chloride and R 1 -X 1 The compound represented by H undergoes a first reaction to obtain a first intermediate, wherein X 1 It is S; (2) without isolating the first intermediate, adding R 2 -X 2 The compound represented by H is subjected to a second reaction in the presence of a base as an acid-binding agent to obtain a second intermediate, wherein X 2 is NH or S; (3) without isolating the second intermediate, adding H2N-(CH2)q-NR 3 R 4 The diamine represented by the present invention is subjected to a third reaction under heating conditions to obtain an amino lipid compound; Wherein, q is an integer from 1 to 12, R 1 , R 2 , R 3 and R 4 The definition is the same as that in any one of claims 1-9.

12. Use of the amino lipid compound according to any one of claims 1 to 10, wherein: The amino lipid compound is used to prepare lipid particles.

13. The use according to claim 12, wherein The lipid particles are lipid nanoparticles, liposomes, multilamellar vesicles or micelles.

14. The use according to claim 12 or 13, wherein The lipid particles are lipid nanoparticles.

15. A lipid particle comprising an amino lipid compound represented by the following chemical formula I: [Chemical Formula I] In Formula I, R 1 and R 2 are the same as or different from each other and are each independently selected from C6-C 24 Alkyl, C6-C 24 Alkenyl, C6-C 24 Alkynyl and C4-C 24 Acyl, wherein The C6-C 24 Alkyl, the C6-C 24 Alkenyl, the C6-C 24 Alkynyl and the C4-C 24 The acyl group is optionally substituted with a C1-C6 hydrocarbon group; X 1 , X 2 and X 3 are the same as or different from each other and are each independently selected from C, N, O, S, S=O, S(=O)2 and SS; When X 1 When it is C, m=2, and two R 6 The same or different from each other; when X 1 When it is N, m=1; when X 1 When it is O, S, S=O, S(=O)2 or SS, m=0; When X 2 When it is C, n=2, and two R 7 The same or different from each other; when X 2 When it is N, n=1; when X 2 When it is O, S, S=O, S(=O)2 or SS, n=0; When X 3 When it is C, p = 2, and the two R 8 The same or different from each other; when X 3 When it is N, p = 1; when X 3 When it is O, S, S=O, S(=O)2 or SS, p=0; R 3 and R 4 are the same as or different from each other and are each independently selected from C1-C 12 Alkyl, C2-C 12 Alkenyl and C2-C 12 Alkynyl, wherein the C1-C 12 Alkyl, the C2-C 12 Alkenyl and the C2-C 12 The alkynyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 Combined with each other to form a 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen, wherein the 4- to 10-membered heterocyclic ring is optionally substituted with a C1-C3 alkyl group; R 5 Does not exist, or R 5 is hydrogen or C1-C 12 Alkyl to provide a quaternary amine; R 6 , R 7 , R 8 is hydrogen or C1-C 12 alkyl; L is C1-C 12 Alkylene, wherein the C1-C 12 The alkylene group is optionally substituted with one or more substituents selected from the group consisting of a hydrocarbyl group, a carboxyl group, an acyl group, and an alkoxy group.

16. The lipid granule according to claim 15, wherein The amino lipid compound, wherein X 1 Selected from C, O, S, S=O, S(=O)2 and SS.

17. The lipid granule according to claim 15, wherein The amino lipid compound, wherein X 1 C, R 6 is H, m = 2; or X 1 N, R 6 is H, m = 1; or X 1 For O, S, S=O, S(=O)2 or SS, m=0; X 2 C, R 7 is H, n = 2; or X 2 N, R 7 is H, n = 1; or X 2 For O, S, S=O, S(=O)2 or SS, n=0; X 3 C, R 8 is H, p = 2; or X 3 N, R 8 is H, p = 1; or X 3 For O, S, S=O, S(=O)2 or SS, p=0.

18. The lipid particle according to claim 15 or 16, wherein The amino lipid compound, wherein R 1 and R 2 are the same or different from each other and are each independently C6-C 24 alkyl; X 1 is S, m=0; X 2 N, R 7 is H, n = 1; or X 2 is S, n = 0; X 3 N, R 8 is H, p = 1; R 3 and R 4 are the same or different from each other and are each independently C 1- C 12 Alkyl, wherein the C 1- C 12 The alkyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 Combined with each other to form a 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen, wherein the 4- to 10-membered heterocyclic ring is optionally substituted with a C1-C3 alkyl group; R 5 Does not exist.

19. The lipid granule according to claim 15, wherein The amino lipid compound, wherein R 1 and R 2 are the same or different from each other and are each independently C6-C 24 alkyl; X 1 N, R 6 is H, m = 1; or X 1 is S, m=0; X 2 N, R 7 is H, n = 1; or X 2 is S, n = 0; X 3 N, R 8 is H, p = 1; R 3 and R 4 are the same or different from each other and are each independently C 1- C 12 Alkyl, wherein the C 1- C 12 The alkyl group is optionally substituted by a C1-C6 hydrocarbon group, or R 3 and R 4 Combined with each other to form a 4- to 10-membered heterocyclic ring containing 1 to 6 heteroatoms selected from nitrogen, sulfur and oxygen, wherein the 4- to 10-membered heterocyclic ring is optionally substituted with a C1-C3 alkyl group; R 5 Does not exist.

20. The lipid particle according to claim 15 or 16, wherein The amino lipid compound, wherein X 1 For S, X 2 N, X 3 is N.

21. according to the lipid particle described in claim 15 or 16, wherein, The amino lipid compound, wherein X 1 For S, X 2 For S, X 3 is N.

22. The lipid granule according to claim 15, wherein The amino lipid compound, wherein X 1 N, X 2 N, X 3 is N.

23. according to the lipid particle described in claim 15 or 16, wherein, The amino lipid compound, wherein L is a C1-C4 alkylene group, wherein the C1-C4 alkylene group is optionally substituted by a C1-C6 hydrocarbon group.

24. according to the lipid particle described in claim 15 or 16, wherein, The amino lipid compound, wherein R 1 and R 2 are the same or different from each other and are each independently C6-C 18 alkyl.

25. lipid granule according to claim 15, wherein, The amino lipid compound, wherein are the same as or different from each other and are each independently selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, 2 N 12 One of: S6:CH3(CH2)5S-; S7:CH3(CH2)6S-; S8:CH3(CH2)7S-; S9:CH3(CH2)8S-;S10:CH3(CH2)9S-;S11:CH3(CH2) 10 S-; S12:CH3(CH2) 11 S-;S14:CH3(CH2) 13 S-;S15:CH3(CH2) 14 S-; S16:CH3(CH2) 15 S-;S18:CH3(CH2) 17 S-; N6:CH3(CH2)5NH-; N7:CH3(CH2)6NH-; N8:CH3(CH2)7NH-; <h2 style=";text-align:left;direction:ltr">N9:CH3(CH2)8NH-;N11:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> NH-;N12:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> NH-; N13:CH3(CH2) 12 NH-;N15:CH3(CH2) 14 NH-;N16:CH3(CH2) 15 NH-; <h2 style=";text-align:left;direction:ltr">N18:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 17 <h2 style=";text-align:left;direction:ltr"> NH-;<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> N<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> :(CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> )2N-; It is one selected from the following D1, D2, D3, D4, D5, D6, D7, D8, D9: D1: D2: D3: D4: D5: D6: D7: D8: D9:

26. A lipid particle comprising an amino lipid compound represented by the following chemical formula I: [Chemical Formula I] in, are the same as or different from each other and are each independently selected from the following S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, 2 N 12 One of: S6:CH3(CH2)5S-; S7:CH3(CH2)6S-; S8:CH3(CH2)7S-; S9:CH3(CH2)8S-;S10:CH3(CH2)9S-;S11:CH3(CH2) 10 S-; S12:CH3(CH2) 11 S-;S14:CH3(CH2) 13 S-;S15:CH3(CH2) 14 S-; S16:CH3(CH2) 15 S-;S18:CH3(CH2) 17 S-; N6:CH3(CH2)5NH-; N7:CH3(CH2)6NH-; N8:CH3(CH2)7NH-; <h2 style=";text-align:left;direction:ltr">N9:CH3(CH2)8NH-;N11:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> NH-;N12:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> NH-; N13:CH3(CH2) 12 NH-;N15:CH3(CH2) 14 NH-;N16:CH3(CH2) 15 NH-; <h2 style=";text-align:left;direction:ltr">N18:CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 17 <h2 style=";text-align:left;direction:ltr"> NH-;<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> N<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> :(CH3(CH2)<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> )2N-; It is D10: D10: 27. according to claim 15,16,17,19,22,25 and 26 any one described lipid particle, wherein, The lipid particles are lipid nanoparticles, liposomes, multilamellar vesicles or micelles.

28. lipid granules according to claim 27, wherein, The lipid particles are lipid nanoparticles.

29. according to any one of the lipid particles in claims 15, 16, 17, 19, 22, 25 and 26, said lipid particle further contains one or more of an auxiliary lipid, a sterol and a bioactive agent.

30. according to the lipid granule described in claim 29, wherein, The helper lipid is a non-cationic lipid.

31. lipid granule according to claim 29, wherein, The helper lipid is a non-cationic phospholipid.

32. lipid granules according to claim 30, wherein, The non-cationic lipid is DOPE.

33. lipid granule according to claim 29, wherein, The sterol is cholesterol.

34. lipid granules according to claim 29, wherein, The bioactive agent is one or more of nucleic acid, peptide, protein and small molecule.

35. lipid granule according to claim 29, wherein, The bioactive agent is one or more of an anti-tumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, and an agent acting on the central nervous system.

36. lipid granule according to claim 29, wherein, The bioactive agent is an antigen or a fragment thereof.

37. lipid granule according to claim 29, wherein, The bioactive agent is a vaccine.

38. according to the lipid granule described in claim 34, wherein, The protein is an antibody.

39. according to the lipid granule described in claim 34, wherein, The nucleic acid is RNA or DNA.

40. according to the lipid granule described in claim 34, wherein, The nucleic acid is an antisense oligonucleotide.

41. according to the lipid granule described in claim 39, wherein, The RNA is mRNA, rRNA, miRNA, tRNA, siRNA or snRNA.

42. according to the lipid granule described in claim 39, wherein, The DNA is a plasmid.

43. Use of the lipid particle described in any one of claims 15 to 42 in the preparation of a medicament, wherein: The drug is a drug for gene therapy, gene vaccination, antisense therapy or therapy by interfering RNA.

44. The use according to claim 43, wherein The gene therapy can be used to treat cancer and genetic diseases.

45. The use according to claim 44, wherein The cancer is one or more of lung cancer, stomach cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphoma, blood cancer or prostate cancer.

46. ​​The use according to claim 44, wherein The genetic disease is one or more of hemophilia, thalassemia, and Gaucher's disease.

47. The use according to claim 43, wherein Such genetic vaccination is used to treat cancer, allergies, toxicity and pathogen infection.

48. The use according to claim 47, wherein The pathogen is one or more of a virus, a bacterium or a fungus.

49. Use of the lipid particle described in any one of claims 15 to 42 in the preparation of a medicament for nucleic acid transfer.

50. The use according to claim 49, wherein The nucleic acid is RNA or DNA.

51. The use according to claim 49, wherein The nucleic acid is an antisense oligonucleotide.

52. The use according to claim 50, wherein The RNA is mRNA, rRNA, miRNA, tRNA, siRNA or snRNA.

53. The use according to claim 50, wherein The DNA is a plasmid.